Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

SEATTLE GENETICS, INC.

(SGEN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/18/2019 06/19/2019 06/20/2019 06/21/2019 06/24/2019 Date
73.14(c) 72.34(c) 72.33(c) 71.74(c) 70.19 Last
767 584 414 952 454 533 1 235 254 24 876 Volume
+2.14% -1.09% -0.01% -0.82% -2.16% Change
More quotes
Financials (USD)
Sales 2019 815 M
EBIT 2019 -228 M
Net income 2019 -177 M
Finance 2019 279 M
Yield 2019 -
Sales 2020 1 057 M
EBIT 2020 -76,6 M
Net income 2020 -64,0 M
Finance 2020 324 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 13,9x
EV / Sales2020 10,6x
Capitalization 11 573 M
More Financials
Company
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed... 
More about the company
Surperformance© ratings of Seattle Genetics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SEATTLE GENETICS, INC.
09:01aSEATTLE GENETICS : Natasha A. Hernday Elected to PDL BioPharma's Board of Direct..
PR
06/13SEATTLE GENETICS : Announces Multiple ADCETRIS Presentations at the Congress of ..
AQ
06/12SEATTLE GENETICS : Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentati..
BU
06/11Seattle Genetics' Antibody-Drug Conjugate Technology Utilized in Genentech's ..
AQ
06/10SEATTLE GENETICS : rsquo; Antibody-Drug Conjugate Technology Utilized in Genente..
BU
06/04SEATTLE GENETICS : and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedo..
AQ
06/04SEATTLE GENETICS : Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phas..
AQ
06/03SEATTLE GENETICS : Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phas..
BU
06/03SEATTLE GENETICS : and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedo..
BU
05/23SEATTLE GENETICS INC /WA : Change in Directors or Principal Officers, Submission..
AQ
More news
Analyst Recommendations on SEATTLE GENETICS, INC.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
06/21Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results
DJ
06/20EXELIXIS : Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint
DJ
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19GILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEATTLE GENETICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 79,5 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson CFO & Principal Accounting Officer
Vaughn B. Himes Chief Technical Officer
Robert J. Lechleider Senior Vice President-Clinical Development
Roger D. Dansey Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.26.61%10 947
IQVIA HOLDINGS INC36.58%26 223
LONZA GROUP28.86%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION39.49%17 061
EXACT SCIENCES CORPORATION83.26%13 037